Gene therapy using adeno-associated virus vectors

Clinical Microbiology Reviews

Volumn 21, Issue 4, 2008, Pages 583-593

  Daya, Shyam ^a   Berns, Kenneth I ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ASPARTOACYLASE; DYSTROPHIN; EYE PROTEIN; FC RECEPTOR; GLUTAMATE DECARBOXYLASE 65; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MINIDYSTROPHIN; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROPEPTIDE Y; NEURTURIN; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN CLN2; PROTEOHEPARAN SULFATE; RETINAL PIGMENT EPITHELIUM SPECIFIC PROTEIN 65; SARCOGLYCAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SERINE PROTEINASE; SIALIC ACID; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; ARTHRITIS; CANAVAN DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; EPILEPSY; GENE EXPRESSION; HEART FAILURE; HEMOPHILIA B; HISTOPLASMOSIS; HUMAN; HUMORAL IMMUNITY; LEBER CONGENITAL AMAUROSIS; LIFE CYCLE; LIPOFUSCINOSIS; LIVER TOXICITY; MUSCULAR DYSTROPHY; NONHUMAN; PARKINSON DISEASE; PARVOVIRUS INFECTION; PROMOTER REGION; PROSTATE CANCER; PROTEIN INTERACTION; REVIEW; SEPSIS; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS CLASSIFICATION; VIRUS GENOME; VIRUS RECOMBINANT;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; HUMANS; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS;

EID: 54249126862     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.00008-08     Document Type: Review

References (80)

1. Afione, S. A., C. K. Conrad, W. G. Kearns, S. Chunduru, R. Adams, T. C. Reynolds, W. B. Guggino, G. R. Cutting, B. J. Carter, and T. R. Flotte. 1996. In vivo model of adeno-associated virus vector persistence and rescue. J. Virol. 70:3235-3241.
2. Aitken, M. L., R. B. Moss, D. A. Waltz, M. E. Dovey, M. R. Tonelli, S. C. McNamara, R. L. Gibson, B. W. Ramsey, B. J. Carter, and T. C. Reynolds. 2001. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12:1907-1916.
3. Akache, B., D. Grimm, K. Pandy, S. R. Yant, Y. Xu, and M. A. Kay. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-9836.
4. Akache, B., D. Grimm, X. Shen, S. Fuess, S. R. Yant, D. S. Glazer, J. Park, and M. A. Kay. 2007. A two-hybrid screen identifies cathepsin B and L as uncoating factors for adeno-associated virus 2 and 8. Mol. Ther. 15:330-339.
5. Anand, V., B. Duffy, Z. Yang, N. S. Dejneka, A. M. Maguire, and J. Bennett. 2002. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol. Ther. 5:125-132.
6. Arnold, G. S., A. K. Sasser, M. D. Stachler, and J. S. Bartlett. 2006. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vectors serotypes. Mol. Ther. 14:97-106.
7. Asokan, A., J. B. Hamra, L. Govindasamy, M. Agbandje-McKenna, and R. J. Samulski. 2006. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80:8961-8969.
8. Bartlett, J. S., J. Kleinschmidt, R. C. Boucher, and R. J. Samulski. 1999. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′gamma)2 antibody. Nat. Biotechnol. 17:181-186.
9. Bartlett, J. S., R. Wilcher, and R. J. Samulski. 2000. Infectious entry pathways of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74:2777-2785.
10. Bleker, S., F. Sonntage, and J. A. Kleinschmidt. 2005. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveal a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79:2528-2540.
11. Brockstedt, D. G., G. M. Podsakoff, L. Fong, G. Kurtzman, W. Mueller-Ruchholtz, and E. G. Engleman. 1999. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on route of administration. Clin. Immunol. 92:67-75.
12. Cao, O., C. Furlan-Frequia, V. R. Arruda, and R. W. Herzong. 2007. Emerging role of regulatory T cells in gene transfer. Curr. Gene Ther. 7:381-390.
13. Chirmule, N., K. J. Propert, S. A. Magosin, Y. Qian, R. Qian, and J. M. Wilson. 1999. Immune response to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1574-1583.
14. Chirmule, N., W. Xiao, A. Truneh, M. A. Schnell, J. V. Hughes, P. Zoltick, and J. M. Wilson. 2000. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and non-human primate muscle. J. Virol. 74:2420-2425.
15. Duan, D., Q. Li, A. W. Kao, Y. Yue, J. E. Pessin, and J. F. Engelhardt. 1999. Dynamin is required for recombinant adeno-associated virus type 2 infection. J. Virol. 73:10371-10376.
16. Dutheil, N., F. Shi, T. Dupressoir, and R. M. Linden. 2000. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc. Natl. Acad. Sci. USA 97:4862-4866.
17. Feigin, A., M. G. Kaplitt, C. Tang, T. Lin, P. Mattis, V. Dhawan, M. J. During, and D. Eidelberg. 2007. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA 104:19559-19564.
18. Feng, D., J. Chen, Y. Yue, H. Zhu, J. Xue, and W. W. Jia. 2006. A 16bp rep binding element is sufficient for mediating rep-dependent integration into AAVS1. J. Mol. Biol. 358:38-45.
19. Ferrari, F. K., T. Samulski, T. Shenk, and R. J. Samulski. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:3227-3234.
20. Fischer, A., S. Hacein-Bey-Abina, C. Lagresle, A. Garrigue, and M. Cavazana-Calvo. 2005. Gene therapy of severe combined immunodeficiency disease: proof of efficiency and safety issues. Bull. Acad. Natl. Med. 189:779-785. (In French.)
21. Fisher, K. J., K. Jooss, J. Alston, Y. Yang, S. E. Haecker, K. High, R. Pathak, S. E. Raper, and J. M. Wilson. 1997. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3:306-312.
22. Flotte, T. R., B. Carter, C. Conrad, W. Guggino, T. Reynolds, B. Rosenstein, G. Taylor, S. Walden, and R. Wetzel. 1996. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther. 7:1145-1149.
23. Flotte, T. R., P. L. Zeitlin, T. C. Reynolds, A. E. Heald, P. Pedersen, S. Beck, C. K. Conrad, L. Brass-Ernst, M. Humphries, K. Sullivan, R. Wetzel, G. Taylor, B. J. Carter, and W. B. Guggino. 2003. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther. 14:1079-1088.
24. Gao, G., L. H. Vandenberge, and J. M. Wilson. 2005. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5:285-297.
25. Ghosh, A., Y. Yue, and D. Dongsheng. 2006. Viral serotype and transgene sequence overlapping adeno-associated virus (AAV) vector-mediated gene transfer in skeletal muscle. J. Gen. Med. 8:298-305.
26. Giraud, C., E. Winocour, and K. I. Berns. 1994. Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence. Proc. Natl. Acad. Sci. USA 91:10039-10043.
27. Girod, A., C. E. Wobus, Z. Zadori, M. Ried, K. Leike, P. Tijssen, J. A. Kleinschmidt, and M. Hallek. 2002. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 83:973-978.
28. Halbert, C. L., T. A. Standaert, C. B. Wilson, and A. D. Miller. 1998. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72:9795-9805.
29. Hansen, J., K. Qing, and A. Srivastava. 2001. Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4:289-296.
30. Hauck, B., W. Zhao, K. High, and W. Xiao. 2004. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J. Virol. 78:13678- 13686.
31. Herzog, R. W., J. N. Hagstrom, S. H. Kung, S. J. Tai, J. M. Wilson, K. J. Fisher, and K. A. High. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94:5804-5809.
32. Herzog, R. W., E. Y. Yang, L. B. Couto, J. N. Hagstrom, D. Elwell, P. A. Fields, M. Burton, D. A. Bellinger, M. S. Read, K. M. Brinkhous, G. M. Podsakoff, T. C. Nichols, G. J. Kurtzman, and K. A. High. 1999. Long-term correction of hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5:56-63.
33. Kaiser, J. 2007. Gene transfer an unlikely contributor to patient's death. Science 318:1535.
34. Kaplitt, M. G., A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor, R. J. Bland, D. Young, K. Strybind, D. Eidelberg, and M. J. During. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-2105.
35. Kashiwakura, Y., K. Tamayose, K. Iwabuchi, Y. Hirai, T. Shimada, K. Matsumoto, T. Nakamura, K. Oshimi, and H. Daida. 2005. Hepatocyte growth factor receptor is a co-receptor for adeno-associated virus type 2 infection. J. Virol. 79:609-614.
36. Kay, M. S., C. S. Manno, M. V. Ragni, P. J. Larson, L. B. Couto, A. McClelland, B. Glader, A. J. Chew, S. J. Tai, R. W. Herzog, V. Arruda, F. Johnson, C. Scallan, E. Skarsgard, A. W. Flake, and K. A. High. 2000. Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. Nat. Genet. 24:257-261.
37. Kotin, R. M., M. Siniscalco, R. J. Samuslki, X. D. Zhu, L. Hunter, C. A. Laughlin, S. McLaughlin, N. Muzyczka, M. Rocchi, and K. I. Berns. 1990. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87:2211-2215.
38. Li, H., S. L. Murphy, W. Giles-Davis, S. Edmonson, Z. Xiang, Li, Y., M. O. Lasaro, K. A. High, and H. C. Ertl. 2007. Pre-existing AAV capsid specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol. Ther. 15:792-800.
39. Liu, X., M. Luo, L. N. Zhang, Z. Yan, R. Zak, W. Ding, S. G. Mansfield, L. G. Mitchell, and J. F. Engelhardt. 2005. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum. Gene Ther. 16:1116-1123.
40. Manning, W. C., S. Zhou, M. P. Bland, J. A. Escobedo, and V. Dwarki. 1998. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9:477-485.
41. Manno, C. S., A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, L. B. Couto, D. G. Leonard, F. A. Johnson, A. McClelland, C. Scallan, E. Skarsgard, A. W. Flake, M. A. Kay, K. A. High, and B. Glader. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972.
42. Manno, C. S., G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, P. K. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F. Wright, R. R. Lessard, J. M. Sommer, M. Tigges, B. Sabatino, A. Luk, H. Jiang, F. Mingossi, L. Couto, H. C. Ertl, K. A. High, and M. A. Kay. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12:342-347.
43. Mastakov, M. Y., K. Baer, C. W. Symes, C. B. Leichtlein, R. M. Kotin, and M. J. During. 2002. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol. 76:8446-8454.
44. McCarty, D. M., P. E. Monahan, and R. J. Samulski. 2001. Self complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 16:1248-1254.
45. Mingozzi, F., M. V. Maus, D. J. Hui, D. E. Sabatino, S. L. Murphy, J. E. Rasko, M. V. Ragni, C. S. Manno, J. Sommer, H. Jiang, G. F. Perce, H. C. Ertl, and K. A. High. 2007. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13:419-422.
46. Moss, R. B., D. Rodman, L. T. Spencer, M. L. Aitken, P. L. Zeitlin, D. Waltz, C. Milla, A. S. Brody, J. P. Clancy, B. Ramsey, N. Hamblett, and D. Milla. 2004. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis; a multicenter, double-blind placebo-controlled trial. Chest 125:509-521.
47. Murphy, S. L., H. Li, S. Zhou, A. Schlachterman, and K. High. 2008. Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol. Ther. 16:138-145.
48. Pereira, D. J., D. M. McCarty, and N. Muzyczka. 1997. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J. Virol. 71:1079-1088.
49. Philpott, N. J., J. Gomos, K. I. Berns, and E. Falck-Pedersen. 2002. A p5 integration efficiency element mediates rep-dependent integration into AAVS1 at chromosome 19. Proc. Natl. Acad. Sci. USA 99:12381-12385.
50. Ponnazhagen, S., G. Mahendra, S. Kumar, J. A. Thompson, and M. Castillas, Jr. 2002. Conjugate-based targeting of recombinant adeno-associated virus type 2 vector using avidin-linked ligands. J. Virol. 76:12900-12907.
51. Qing, K., J. Hansen, K. A. Weigel-Kelley, M. Tan, S. Zhou, and A. Srivastava. 2001. Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J. Virol. 75:8968-8976.
52. Qing, K., W. Li, L. Zhong, M. Tan, J. Hansen, K. A. Wiegel-Kelly, L. Chen, M. C. Yoder, and A. Srivastava. 2003. Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo. J. Virol. 77:2741-2746.
53. Qing, K., C. Mah, J. Hansen, S. Zhou, V. Dwarki, and A. Srivastava. 1999. Human fibroblast growth factor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77.
54. Recchia, A., L. Perani, D. Sartori, C. Olgiati, and F. Malvilio. 2004. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 10:660-670.
55. Reich, S. J., A. Auricchio, M. Hildinger, E. Glover, A. M. Maguire, J. M. Wilson, and J. Bennett. 2003. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum. Gene Ther. 14:37-44.
56. Rizzuto, G., B. Gorgoni, M. Cappelletti, D. Lazzaro, G. Ciliberto, I. Gloaguen, V. Poli, A. Sgura, D. Cimini, R. Cortese, E. Fattori, and N. La Monica. 1999. Development of animal models for adeno-associated virus site-specific integration. J. Virol. 73:2517-2526.
57. Sanlioglu, S., P. K. Benson, J. Yang, E. M. Atkinson, T. Reynolds, and J. F. Engelhardt. 2000. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Rac1 and phophatidylinositol-3 kinase activation. J. Virol. 74:9184-9196.
58. Schmidt, M., S. Afione, and R. M. Kotin. 2000. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J. Virol. 74:9441-9450.
59. Schnepp, B. C., R. L. Jensen, C. L. Chen, P. R. Johnson, and K. R. Clark. 2005. Characterization of adeno-associated virus genomes isolated from human tissues. J. Virol. 79:4793-4803.
60. Srivastava, A., E. W. Lusby, and K. I. Berns. 1983. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45:555-564.
61. Stachler, M. D., and J. S. Bartlett. 2006. Mosaic vectors comprised of modified AAV 1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13:926-931.
62. Summerford, C., and R. J. Samulski. 1998. Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
63. 5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82.
64. Tan, I., C. H. Ng, L. Lim, and T. Leung. 2001. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J. Biol. Chem. 276:21209-21216.
65. Vandenberghe, L. H., L. Wang, S. Somanathan, Y. Zhi, J. Figueredo, R. Calcedo, J. Sanmiguel, R. A. Desai, C. S. Chen, J. Johnston, R. L. Grant, G. P. Gao, and J. M. Wilson. 2006. Heparin binding directs activation of T-cells against adeno-associated virus serotype 2 capsid. Nat. Med. 12:967-971.
66. Wagner, J. A., T. Reynolds, M. L. Moran, R. B. Moss, J. J. Wine, T. R. Flotte, and P. Gardner. 1998. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351:1702-1703.
67. Wang, L., J. Figueredo, R. Calcedo, J. Lin, and J. M. Wilson. 2007. Cross-presentation of adeno-associated virus serotype 2 capsids activated cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum. Gene Ther. 18:185-194.
68. Weitzman, M. D., S. Kyostio, R. M. Kotin, and R. A. Owens. 1994. Adeno-associated virus (AAV) rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc. Natl. Acad. Sci. USA 91:5808-5812.
69. White, S. J., S. A. Nicklin, H. Buning, M. J. Brosnan, K. Leike, E. D. Papadakis, M. Hallek, and A. H. Baker. 2004. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109:513-519.
70. Williams, D. 2007. A RAC reviews serious adverse event associated with AAV therapy trial. Mol. Ther. 15:2053.
71. Wu, J., W. Zhao, L. Zhong, Z. Han, B. Li, W. Ma, K. A. Weigel-Kelley, K. H. Warrington, and A. Srivastava. 2007. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of the rep proteins in vectors purity. Hum. Gene Ther. 18:171-182.
72. Xiao, X., J. Li, and R. J. Samulski. 1996. Efficient long-term gene transfer into muscle of immunocompetent mice by adeno-associated virus vectors. J. Virol. 70:8098-8108.
73. Yamamoto, N., M. Suzuki, M. A. Kawano, T. Inoue, R. U. Takahashi, H. Tsukamoto, T. Enomoto, Y. Yamaguchi, T. Wada, and H. Handa. 2007. Adeno-associated virus site-specific integration is regulated by TRP-185. J. Virol. 81:1990-2001.
74. Yan, Z., Y. Zhang, D. Duan, and J. F. Engelhardt. 2000. trans-Splicing vectors expand utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA 97:6716-6721.
75. Yang, Q., F. Chen, and J. P. Trempe. 1994. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol. 68:4847-4856.
76. Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, and D. A. Muruve. 2002. Differential activation of innate immune response by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.
77. Zhang, C., N. Cortez, and K. I. Berns. 2007. Characterization of a bipartite recombinant adeno-associated virus vector for site-specific integration. Hum. Gene Ther. 18:787-797.
78. Zhang, Y. I., N. Chirmule, G. P. Gao, and J. M. Wilson. 2000. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vector in vivo: role of immature dendritic cells. J. Virol. 74:8003-8010.
79. Zhao, W., J. Wu, L. Zhong, and A. Srivastava. 2007. Adeno-associated virus 2-mediated gene transfer: role of a cellular serine/threonine protein phosphatase in augmenting transduction efficiency. Gene Ther. 14:545-550.
80. Zhong, L., W. Zhao, J. Wu, B. Li, S. Zolotukhin, L. Govindasamy, M. Agbandje-McKenna, and A. Srivastava. 2007. A dual-role of EGFR protein kinase signaling in ubiquitination of AAV 2 capsids and viral second strand synthesis. Mol. Ther. 17:1323-1330.